These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://amiezflj091792.blogozz.com/38026870/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide